Video

Dr. Nickel discusses the safety of novel recurrent UTI vaccine

Author(s):

Urology Times staff

“It is a vaccine that is self-administered by the patient sublingual over 3 months, and that is why it appears to be so safe,” says J. Curtis Nickel, MD.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, J. Curtis Nickel, MD, discusses the safety of the MV140 vaccine, used to treat patients with recurrent urinary tract infections. Nickel is a professor of the department of urology at Queen’s University and urologist at Kingston and Hotel Dieu General Hospitals, Kingston, Ontario, Canada.

      Related Videos
      Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
      Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      BLUES trial: Silicone stents may improve patient care
      Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
      Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
      Jared S. Winoker, MD, answers a question during a Zoom video interview
      Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      Jim Hu, MD, on urinary continence recovery across RARP techniques
      Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
      Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
      Mohit Khera, MD, on the impact of penile prosthesis implant on mental health
      Mohit Khera, MD, on the impact of penile prosthesis implant on mental health
      Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
      Special Report: Tips for PCPs on evaluating prostate cancer risk
      Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
      Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
      Related Content
      Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
      May 16th 2025

      Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

      Melissa Kaufman, MD, PhD, FACS Hannah Clarke
      The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
      Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025
      April 29th 2025

      Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

      Amy M. Pearlman, MD Rachel Rubin, MD
      Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.
      Hospital waiting room with reception counter at medical facility | Image Credit: © visoot - stock.adobe.com
      April 5th 2025

      Vaginal prolapse repair and sling surgery significantly reduce UUI

      Christina M. Mezes, DO Catherine A. Matthews, MD
      "The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.
      Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause
      April 28th 2025

      Speaking of Urology: Melissa Kaufman, MD, on AUA’s new guideline on genitourinary syndrome of menopause

      Melissa Kaufman, MD, PhD, FACS
      In this episode, guideline chair Melissa Kaufman, MD, PhD, FACS, highlights key points from the new AUA GSM guideline and illustrates its impact for clinical management of this condition.
      FDA grants marketing authorization to at-home diagnostic test for STIs
      March 28th 2025

      FDA grants marketing authorization to at-home diagnostic test for STIs

      Hannah Clarke
      The test can deliver diagnostic results for chlamydia, gonorrhea, and trichomoniasis.
      Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
      March 25th 2025

      Expert discusses unique mechanism of action of UTI treatment gepotidacin

      Ryan Haumschild, PharmD, MS, MBA, CPEL
      "I think [gepotidacin] gives a different side effect profile available to the clinicians, and I think for patients as well, it provides a better, more durable option over time," says Ryan Haumschild, PharmD, MS, MBA, CPEL.
      © 2025 MJH Life Sciences

      All rights reserved.